Abstract
Aim: Treatment-resistant depression patients are more likely to suffer from comorbid physical and mental disorders, experience marked and protracted functional impairment, and incur higher health-care costs than non-affected individuals. Magnesium sulfate is a treatment option that may offer great potential for patients with treatment-resistant depression based on prior work in animals and humans. Methods: Twelve subjects with mild or moderate treatment-resistant depression were randomized into a double-blind crossover trial to receive an infusion of 4g of magnesium sulfate in 5% dextrose or placebo infusion of 5% dextrose with a 5-day washout in between the 8-day intervention period. Subjects were assessed before and after the intervention for serum and urine magnesium, lipid panel, the Hamilton Rating Scale for Depression, and the Patient Health Questionnaire-9. Results: We found a difference in serum magnesium from day 2 to 8 (pre-infusion) (P< 0.002) and from baseline to day 8 (P< 0.02). No changes were noted on the Hamilton Rating Scale for Depression or the Patient Health Questionnaire-9 24h post-treatment, but as serum magnesium increased from baseline to day 7, the Patient Health Questionnaire-9 decreased from baseline to day 7 (P=0.02). Conclusion: Magnesium sulfate did not significantly affect depression 24h post-infusion, but other results were consistent with the literature. The association between changes in serum magnesium and the Patient Health Questionnaire-9 supports the idea that magnesium sulfate may be used to address treatment-resistant depression, an ongoing medical challenge.
| Original language | English (US) |
|---|---|
| Journal | Psychiatry and Clinical Neurosciences |
| DOIs | |
| State | Accepted/In press - 2016 |
Fingerprint
Keywords
- Depressive symptoms
- Intervention study
- Intravenous infusions
- Magnesium sulfate
- Treatment-resistant depression
ASJC Scopus subject areas
- Neuroscience(all)
- Neurology
- Clinical Neurology
- Psychiatry and Mental health
Cite this
Double-blind, randomized crossover study of intravenous infusion of magnesium sulfate versus 5% dextrose on depressive symptoms in adults with treatment-resistant depression. / Mehdi, Syed M A; Atlas, Steven E.; Qadir, Sidra; Musselman, Dominique; Goldberg, Sharon; Woolger, Judi; Corredor, Raul; Abbas, Muhammad H.; Arosemena, Leopoldo; Caccamo, Simone; Campbell, Carmen S G; Farooqi, Ashar; Gao, Jinrun; Konefal, Janet; Lages, Lucas C.; Lantigua, Laura; Lopez, Johanna; Padilla, Vanessa; Rasul, Ammar; Ray, Anna M.; Simões, Herbert G.; Tiozzo, Eduard; Lewis, John E.
In: Psychiatry and Clinical Neurosciences, 2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Double-blind, randomized crossover study of intravenous infusion of magnesium sulfate versus 5% dextrose on depressive symptoms in adults with treatment-resistant depression
AU - Mehdi, Syed M A
AU - Atlas, Steven E.
AU - Qadir, Sidra
AU - Musselman, Dominique
AU - Goldberg, Sharon
AU - Woolger, Judi
AU - Corredor, Raul
AU - Abbas, Muhammad H.
AU - Arosemena, Leopoldo
AU - Caccamo, Simone
AU - Campbell, Carmen S G
AU - Farooqi, Ashar
AU - Gao, Jinrun
AU - Konefal, Janet
AU - Lages, Lucas C.
AU - Lantigua, Laura
AU - Lopez, Johanna
AU - Padilla, Vanessa
AU - Rasul, Ammar
AU - Ray, Anna M.
AU - Simões, Herbert G.
AU - Tiozzo, Eduard
AU - Lewis, John E
PY - 2016
Y1 - 2016
N2 - Aim: Treatment-resistant depression patients are more likely to suffer from comorbid physical and mental disorders, experience marked and protracted functional impairment, and incur higher health-care costs than non-affected individuals. Magnesium sulfate is a treatment option that may offer great potential for patients with treatment-resistant depression based on prior work in animals and humans. Methods: Twelve subjects with mild or moderate treatment-resistant depression were randomized into a double-blind crossover trial to receive an infusion of 4g of magnesium sulfate in 5% dextrose or placebo infusion of 5% dextrose with a 5-day washout in between the 8-day intervention period. Subjects were assessed before and after the intervention for serum and urine magnesium, lipid panel, the Hamilton Rating Scale for Depression, and the Patient Health Questionnaire-9. Results: We found a difference in serum magnesium from day 2 to 8 (pre-infusion) (P< 0.002) and from baseline to day 8 (P< 0.02). No changes were noted on the Hamilton Rating Scale for Depression or the Patient Health Questionnaire-9 24h post-treatment, but as serum magnesium increased from baseline to day 7, the Patient Health Questionnaire-9 decreased from baseline to day 7 (P=0.02). Conclusion: Magnesium sulfate did not significantly affect depression 24h post-infusion, but other results were consistent with the literature. The association between changes in serum magnesium and the Patient Health Questionnaire-9 supports the idea that magnesium sulfate may be used to address treatment-resistant depression, an ongoing medical challenge.
AB - Aim: Treatment-resistant depression patients are more likely to suffer from comorbid physical and mental disorders, experience marked and protracted functional impairment, and incur higher health-care costs than non-affected individuals. Magnesium sulfate is a treatment option that may offer great potential for patients with treatment-resistant depression based on prior work in animals and humans. Methods: Twelve subjects with mild or moderate treatment-resistant depression were randomized into a double-blind crossover trial to receive an infusion of 4g of magnesium sulfate in 5% dextrose or placebo infusion of 5% dextrose with a 5-day washout in between the 8-day intervention period. Subjects were assessed before and after the intervention for serum and urine magnesium, lipid panel, the Hamilton Rating Scale for Depression, and the Patient Health Questionnaire-9. Results: We found a difference in serum magnesium from day 2 to 8 (pre-infusion) (P< 0.002) and from baseline to day 8 (P< 0.02). No changes were noted on the Hamilton Rating Scale for Depression or the Patient Health Questionnaire-9 24h post-treatment, but as serum magnesium increased from baseline to day 7, the Patient Health Questionnaire-9 decreased from baseline to day 7 (P=0.02). Conclusion: Magnesium sulfate did not significantly affect depression 24h post-infusion, but other results were consistent with the literature. The association between changes in serum magnesium and the Patient Health Questionnaire-9 supports the idea that magnesium sulfate may be used to address treatment-resistant depression, an ongoing medical challenge.
KW - Depressive symptoms
KW - Intervention study
KW - Intravenous infusions
KW - Magnesium sulfate
KW - Treatment-resistant depression
UR - http://www.scopus.com/inward/record.url?scp=85007413626&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007413626&partnerID=8YFLogxK
U2 - 10.1111/pcn.12480
DO - 10.1111/pcn.12480
M3 - Article
JO - Psychiatry and Clinical Neurosciences
JF - Psychiatry and Clinical Neurosciences
SN - 1323-1316
ER -